Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Professor and Vice Chair for Research
Psychiatry and Behavioral Sciences
Baylor College of Medicine
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
The Global Medical Education planner and manager, Prakash Masand, MD, has disclosed the following:
Consultant: Acadia, Allergan, Eisai, Intra-Cellular Therapies, Lundbeck, Sunovion, Takeda
Research Support: Allergan
Speaker’s Bureau: Allergan, Intra-Cellular Therapies, Lundbeck, Sunovion, Takeda
Shareholder: Centers of Psychiatric Excellence (COPE), Global Medical Education
The PIM planners and managers have nothing to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is intended for physicians, physician assistants, nurse practitioners, registered nurses, pharmacists and psychologists engaged in the care of patients with mood disorders.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour. Designated for 0.0 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
California Board of Registered Nursing
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1 contact hour.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number –JA4008162-9999-21-2596-H01-P
Type of Activity: Knowledge
AAPA Credit Designation Statement
This activity is designated for 1 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Continuing Psychologist Education
Continuing education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility of the program.
This program offers 1.0 continuing education credit for psychologists.
This program has been made available online.
Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 22, 2021, through February 22, 2022:
1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.
Dr John M. Kane presents an expert’s guide to tardive dyskinesia, from Clinical Care Options (CCO)
Dr. Greg Mattingly reviews recent advances in treating schizophrenia, from Clinical Care Options (CCO)
Sanjay Gupta, MD, on salient research studies of interest relevant to neuroscience, including agitation in dementia, insomnia, antipsychotics in schizophrenia, COVID-19, and provides clinical commentary from Clinical Care Options (CCO)
Slides from a presentation that educates clinicians on managing side effects of psychiatric medications.